MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited Revenue 2011-2026 | VNRX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.23 M | 775 K | 306 K | 90 K | - | 17.1 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.23 M | 17.1 K | 484 K |
Quarterly Revenue VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 627 K | 407 K | 246 K | - | 475 K | 396 K | 172 K | - | 165 K | 216 K | 150 K | - | 32.7 K | 39.8 K | 114 K | - | 25.5 K | 24.8 K | 25.5 K | - | 575 | 5.19 K | 544 | - | 17.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.8 K | - | - | - | - | - | - | - | 27.6 K | 11.7 K | 15.7 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 627 K | 544 | 140 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.82 | -4.73 % | $ 91.5 K |  USA |
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
6.32 B | $ 117.0 | -0.96 % | $ 35.6 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
332 M | $ 27.61 | -1.36 % | $ 767 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 174.64 | -2.24 % | $ 8.66 B | USA |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 13.86 | -2.43 % | $ 419 M | USA |
|
Biodesix
BDSX
|
71.3 M | $ 15.89 | 0.89 % | $ 2.06 B | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
30.8 M | $ 1.1 | -3.42 % | $ 1.4 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 207.28 | -1.42 % | $ 23 B | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 201.9 | -1.94 % | $ 144 B | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | $ 103.4 | 0.04 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
512 M | $ 8.7 | -0.8 % | $ 545 M | USA |
 |
DarioHealth Corp.
DRIO
|
20.4 M | $ 10.5 | -2.33 % | $ 298 M |  Israel |
 |
DexCom
DXCM
|
4.66 B | $ 72.61 | -1.59 % | $ 28.3 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 24.2 | -5.62 % | $ 254 M | China |
 |
CareDx, Inc
CDNA
|
380 M | $ 18.39 | -1.89 % | $ 980 M | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 106.33 | -1.79 % | $ 8.77 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
4.3 B | $ 634.75 | -0.31 % | $ 51.1 B | USA |
 |
Illumina
ILMN
|
4.37 B | $ 129.57 | -2.5 % | $ 20.6 B | USA |
 |
Guardant Health
GH
|
982 M | $ 91.1 | -1.23 % | $ 11.4 B | USA |
 |
IQVIA Holdings
IQV
|
16.3 B | $ 171.85 | -1.39 % | $ 29.5 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 281.58 | -1.63 % | $ 23.4 B | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 76.74 | 0.58 % | $ 5.18 B | USA |
 |
Brainsway Ltd.
BWAY
|
41 M | $ 23.13 | -2.36 % | $ 99.4 M | Israel |
 |
Co-Diagnostics
CODX
|
6.81 M | - | - | $ 79.8 M | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 308.65 | -1.09 % | $ 27 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
824 M | $ 5.03 | 0.4 % | $ 466 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 9.23 | -2.84 % | $ 1.18 B | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
820 M | $ 204.95 | 2.39 % | $ 20.2 B | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.51 | -7.1 % | $ 453 M | USA |
 |
Neogen Corporation
NEOG
|
895 M | $ 10.92 | -2.06 % | $ 2.37 B | USA |
 |
Precipio
PRPO
|
15.2 M | $ 24.5 | -0.73 % | $ 31.8 M | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |